Vistagen Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Vistagen Therapeutics

11/02/2025 21:34

* Vistagen Therapeutics Inc  VTGN.OQ   VTGN.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
13 for the period ending December 31 2024
    * The South San Francisco California-based  company is
expected to
report a 56.2% decrease in revenue to $180 thousand from $411.4
thousand a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Vistagen Therapeutics
Inc is
for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vistagen
Therapeutics Inc is $12.00​, above​ its last closing price
of $2.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.39       -0.39      -0.42     Missed  -7.7
 Jun. 30 2024  -0.41       -0.40      -0.35     Beat    13.6
 Mar. 31 2024  -0.33       -0.36      -0.25     Beat    31​
 Dec. 31 2023  -0.28       -0.30      -0.22     Beat    27.3
 ​​Sep.        -0.68       -0.68      -0.66     Beat    2.9
 30 2023                                                
                                                        ​
 Mar. 31 2023              -1.50      -1.75     Missed  -16.7
 Dec. 31 2022  -2.40       -2.10      -1.50     Beat    28.6
 This summary was machine generated February 11 at 21:34 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)